OR WAIT null SECS
Accelerated Enrollment Solutions (AES), a business unit of Pharmaceutical Product Development, LLC (PPD), has acquired the clinical research site business of Bioclinica, expanding AES’ global footprint in patient access and site conduct. AES services now extend across five continents, 20 countries, over 180 research sites and more than 100 million households.
The acquisition extends AES’ reach into new geographies in China, Latin America and Western Europe, augmenting its strong presence in North America, Europe and South Africa. The transaction includes research sites from the merger of Bioclinica and CCBR-SYNARC in 2014. AES also expands its therapeutic area scope within the United States, adding four dedicated research sites in Florida, branded Compass Research, with significant expertise in neuroscience.
AES’ delivery model aligns the fundamental components of the clinical trial supply chain-sites, patient recruitment and a large aggregation of fully identified, consented data on patients interested in participating in trials. AES provides highly differentiated services for site conduct and patient delivery, aiming to set a new standard in clinical trial productivity-delivering more patients from fewer sites in less time.
“With these new assets operating on five continents, AES is a place where customers can receive 50-100% of their entire trial enrollment from one accountable solution, delivered by research locations that operate uniformly across the globe,” said Roger Smith, senior vice president and general manager of AES. “We can now address two major impediments to meaningful improvement in site selection and patient enrollment-namely, investigator site capacity and the ability to predictably bring new patients into research with our data modeling and analytical capabilities. Our approach can reduce customers’ reliance on patient availability from investigator databases and practices. As we focus on delivering this value for our customers, we are pleased to welcome our new colleagues to AES to be part of our solution-oriented culture and help advance drug development to improve patients’ lives.”
David Herron, president and CEO of Bioclinica, said, “We believe PPD’s AES business unit is an outstanding strategic fit for the global site business. Both organizations have long been committed to clinical research and together they will provide excellent value for sponsors and CROs. This transaction enables AES to take patient access and site conduct to a new level, while enabling Bioclinica to accelerate its delivery of exceptional services in medical imaging, cardiovascular safety, eClinical and trial software, and drug safety solutions.”